(BVI) Bureau Veritas - Overview
Exchange: PA •
Country: France •
Currency: EUR •
Type: Common Stock •
ISIN: FR0006174348
Stock: Testing, Inspection, Certification, Auditing, Compliance
Total Rating 57
Risk 97
Buy Signal -0.47
| Risk 5d forecast | |
|---|---|
| Volatility | 21.1% |
| Relative Tail Risk | -5.98% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.19 |
| Alpha | -4.75 |
| Character TTM | |
|---|---|
| Beta | 0.389 |
| Beta Downside | 0.270 |
| Drawdowns 3y | |
|---|---|
| Max DD | 20.96% |
| CAGR/Max DD | 0.28 |
Description: BVI Bureau Veritas March 04, 2026
Bureau Veritas SA (BVI) provides laboratory testing, inspection, and certification services across diverse sectors. The companys business model involves verifying compliance with regulatory or self-imposed standards for products, assets, and management systems, issuing compliance reports.
Its operations are divided into six segments, including Marine & Offshore and Agri-Food & Commodities. The testing, inspection, and certification (TIC) sector is characterized by a high degree of regulation and technical expertise requirements.
BVI serves a wide range of industries, such as construction, oil and gas, and consumer products, operating globally in approximately 140 countries. This extensive geographic reach is common for major TIC providers.
To gain a deeper understanding of BVIs performance, consider exploring its historical data on ValueRay.
Headlines to watch out for
- Global trade volume impacts inspection and certification demand
- Regulatory changes create new compliance service opportunities
- Commodity price volatility affects Agri-Food & Commodities segment
- Infrastructure spending drives Buildings & Infrastructure revenue
- Labor costs influence service delivery profitability
Piotroski VR‑10 (Strict, 0-10) 10.0
| Net Income: 1.16b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.24 > 0.02 and ΔFCF/TA 7.30 > 1.0 |
| NWC/Revenue: 8.99% < 20% (prev 12.49%; Δ -3.50% < -1%) |
| CFO/TA 0.28 > 3% & CFO 1.96b > Net Income 1.16b |
| Net Debt (2.07b) to EBITDA (2.22b): 0.93 < 3 |
| Current Ratio: 1.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (445.7m) vs 12m ago -2.73% < -2% |
| Gross Margin: 43.06% > 18% (prev 0.29%; Δ 4277 % > 0.5%) |
| Asset Turnover: 186.8% > 50% (prev 151.6%; Δ 35.23% > 0%) |
| Interest Coverage Ratio: 8.22 > 6 (EBITDA TTM 2.22b / Interest Expense TTM 199.1m) |
Altman Z'' 3.78
| A: 0.16 (Total Current Assets 3.31b - Total Current Liabilities 2.16b) / Total Assets 7.06b |
| B: 0.23 (Retained Earnings 1.66b / Total Assets 7.06b) |
| C: 0.24 (EBIT TTM 1.64b / Avg Total Assets 6.85b) |
| D: 0.32 (Book Value of Equity 1.71b / Total Liabilities 5.31b) |
| Altman-Z'' Score: 3.78 = AA |
Beneish M -3.41
| DSRI: 0.78 (Receivables 1.94b/1.94b, Revenue 12.80b/10.07b) |
| GMI: 0.68 (GM 43.06% / 29.18%) |
| AQI: 1.01 (AQ_t 0.42 / AQ_t-1 0.41) |
| SGI: 1.27 (Revenue 12.80b / 10.07b) |
| TATA: -0.11 (NI 1.16b - CFO 1.96b) / TA 7.06b) |
| Beneish M-Score: -3.41 (Cap -4..+1) = AA |
What is the price of BVI shares?
As of March 11, 2026, the stock is trading at EUR 28.52 with a total of 1,105,482 shares traded.
Over the past week, the price has changed by +0.42%, over one month by +0.92%, over three months by +10.54% and over the past year by -0.82%.
Over the past week, the price has changed by +0.42%, over one month by +0.92%, over three months by +10.54% and over the past year by -0.82%.
Is BVI a buy, sell or hold?
Bureau Veritas has no consensus analysts rating.
What are the forecasts/targets for the BVI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 33.9 | 18.7% |
| Analysts Target Price | - | - |
BVI Fundamental Data Overview March 09, 2026
Market Cap USD = 14.71b (12.78b EUR * 1.1513 EUR.USD)
P/E Trailing = 21.9847
P/E Forward = 18.8324
P/S = 1.9124
P/B = 7.4677
P/EG = 2.5098
Revenue TTM = 12.80b EUR
EBIT TTM = 1.64b EUR
EBITDA TTM = 2.22b EUR
Long Term Debt = 2.39b EUR (from longTermDebt, last quarter)
Short Term Debt = 347.9m EUR (from shortTermDebt, last quarter)
Debt = 3.43b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.07b EUR (from netDebt column, last quarter)
Enterprise Value = 14.84b EUR (12.78b + Debt 3.43b - CCE 1.37b)
Interest Coverage Ratio = 8.22 (Ebit TTM 1.64b / Interest Expense TTM 199.1m)
EV/FCF = 8.89x (Enterprise Value 14.84b / FCF TTM 1.67b)
FCF Yield = 11.25% (FCF TTM 1.67b / Enterprise Value 14.84b)
FCF Margin = 13.04% (FCF TTM 1.67b / Revenue TTM 12.80b)
Net Margin = 9.04% (Net Income TTM 1.16b / Revenue TTM 12.80b)
Gross Margin = 43.06% ((Revenue TTM 12.80b - Cost of Revenue TTM 7.29b) / Revenue TTM)
Gross Margin QoQ = 5.32% (prev 23.27%)
Tobins Q-Ratio = 2.10 (Enterprise Value 14.84b / Total Assets 7.06b)
Interest Expense / Debt = 1.79% (Interest Expense 61.6m / Debt 3.43b)
Taxrate = 35.08% (146.9m / 418.7m)
NOPAT = 1.06b (EBIT 1.64b * (1 - 35.08%))
Current Ratio = 1.53 (Total Current Assets 3.31b / Total Current Liabilities 2.16b)
Debt / Equity = 2.01 (Debt 3.43b / totalStockholderEquity, last quarter 1.71b)
Debt / EBITDA = 0.93 (Net Debt 2.07b / EBITDA 2.22b)
Debt / FCF = 1.24 (Net Debt 2.07b / FCF TTM 1.67b)
Total Stockholder Equity = 1.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.89% (Net Income 1.16b / Total Assets 7.06b)
RoE = 68.54% (Net Income TTM 1.16b / Total Stockholder Equity 1.69b)
RoCE = 40.11% (EBIT 1.64b / Capital Employed (Equity 1.69b + L.T.Debt 2.39b))
RoIC = 25.65% (NOPAT 1.06b / Invested Capital 4.14b)
WACC = 6.04% (E(12.78b)/V(16.21b) * Re(7.35%) + D(3.43b)/V(16.21b) * Rd(1.79%) * (1-Tc(0.35)))
Discount Rate = 7.35% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.37%
[DCF] Terminal Value 87.93% ; FCFF base≈1.44b ; Y1≈1.77b ; Y5≈3.02b
[DCF] Fair Price = 184.3 (EV 83.84b - Net Debt 2.07b = Equity 81.77b / Shares 443.7m; r=6.04% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -10.98 | EPS CAGR: -42.03% | SUE: 0.0 | # QB: 0
Revenue Correlation: 47.67 | Revenue CAGR: 10.62% | SUE: 0.00 | # QB: 0
EPS current Year (2026-12-31): EPS=1.57 | Chg7d=-0.001 | Chg30d=+0.010 | Revisions Net=+1 | Growth EPS=+10.6% | Growth Revenue=+4.9%
EPS next Year (2027-12-31): EPS=1.70 | Chg7d=+0.011 | Chg30d=+0.019 | Revisions Net=+3 | Growth EPS=+8.3% | Growth Revenue=+6.2%
[Analyst] Revisions Ratio: +0.14 (4 Up / 3 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 3.4% (Discount Rate 7.9% - Earnings Yield 4.5%)
[Growth] Growth Spread = +2.8% (Analyst 6.2% - Implied 3.4%)
P/E Trailing = 21.9847
P/E Forward = 18.8324
P/S = 1.9124
P/B = 7.4677
P/EG = 2.5098
Revenue TTM = 12.80b EUR
EBIT TTM = 1.64b EUR
EBITDA TTM = 2.22b EUR
Long Term Debt = 2.39b EUR (from longTermDebt, last quarter)
Short Term Debt = 347.9m EUR (from shortTermDebt, last quarter)
Debt = 3.43b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.07b EUR (from netDebt column, last quarter)
Enterprise Value = 14.84b EUR (12.78b + Debt 3.43b - CCE 1.37b)
Interest Coverage Ratio = 8.22 (Ebit TTM 1.64b / Interest Expense TTM 199.1m)
EV/FCF = 8.89x (Enterprise Value 14.84b / FCF TTM 1.67b)
FCF Yield = 11.25% (FCF TTM 1.67b / Enterprise Value 14.84b)
FCF Margin = 13.04% (FCF TTM 1.67b / Revenue TTM 12.80b)
Net Margin = 9.04% (Net Income TTM 1.16b / Revenue TTM 12.80b)
Gross Margin = 43.06% ((Revenue TTM 12.80b - Cost of Revenue TTM 7.29b) / Revenue TTM)
Gross Margin QoQ = 5.32% (prev 23.27%)
Tobins Q-Ratio = 2.10 (Enterprise Value 14.84b / Total Assets 7.06b)
Interest Expense / Debt = 1.79% (Interest Expense 61.6m / Debt 3.43b)
Taxrate = 35.08% (146.9m / 418.7m)
NOPAT = 1.06b (EBIT 1.64b * (1 - 35.08%))
Current Ratio = 1.53 (Total Current Assets 3.31b / Total Current Liabilities 2.16b)
Debt / Equity = 2.01 (Debt 3.43b / totalStockholderEquity, last quarter 1.71b)
Debt / EBITDA = 0.93 (Net Debt 2.07b / EBITDA 2.22b)
Debt / FCF = 1.24 (Net Debt 2.07b / FCF TTM 1.67b)
Total Stockholder Equity = 1.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.89% (Net Income 1.16b / Total Assets 7.06b)
RoE = 68.54% (Net Income TTM 1.16b / Total Stockholder Equity 1.69b)
RoCE = 40.11% (EBIT 1.64b / Capital Employed (Equity 1.69b + L.T.Debt 2.39b))
RoIC = 25.65% (NOPAT 1.06b / Invested Capital 4.14b)
WACC = 6.04% (E(12.78b)/V(16.21b) * Re(7.35%) + D(3.43b)/V(16.21b) * Rd(1.79%) * (1-Tc(0.35)))
Discount Rate = 7.35% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.37%
[DCF] Terminal Value 87.93% ; FCFF base≈1.44b ; Y1≈1.77b ; Y5≈3.02b
[DCF] Fair Price = 184.3 (EV 83.84b - Net Debt 2.07b = Equity 81.77b / Shares 443.7m; r=6.04% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -10.98 | EPS CAGR: -42.03% | SUE: 0.0 | # QB: 0
Revenue Correlation: 47.67 | Revenue CAGR: 10.62% | SUE: 0.00 | # QB: 0
EPS current Year (2026-12-31): EPS=1.57 | Chg7d=-0.001 | Chg30d=+0.010 | Revisions Net=+1 | Growth EPS=+10.6% | Growth Revenue=+4.9%
EPS next Year (2027-12-31): EPS=1.70 | Chg7d=+0.011 | Chg30d=+0.019 | Revisions Net=+3 | Growth EPS=+8.3% | Growth Revenue=+6.2%
[Analyst] Revisions Ratio: +0.14 (4 Up / 3 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 3.4% (Discount Rate 7.9% - Earnings Yield 4.5%)
[Growth] Growth Spread = +2.8% (Analyst 6.2% - Implied 3.4%)